We use cookies on our website. Carry on browsing if you’re happy with this or find out more

IntelliSelect®

Deep mining of Kymab's antibody repertoire

We believe our IntelliSelect® Technology platforms reduce the risk of missing novel solutions and increase the quality and differentiation of antibodies, to identify product candidates with the most desirable drug-like properties.

Intelliselect Updated Image

The IntelliSelect® Transgenics platforms are designed to generate fully-human monoclonal antibodies from highly-engineered strains of mice that have the complete constellation of human antibody building blocks in their genome. They are designed to produce fully human antibodies and we believe they are the most advanced human-antibody generation platforms developed.

Our IntelliSelect® Screening technology combines single-cell sequencing, genomics and proprietary bioinformatic algorithms to prioritize and select antibodies generated by our IntelliSelect® Transgenic platforms that have the most desirable drug-like properties.

Our unique platforms can deliver the finest novel therapeutic antibodies

Learn more